ERBB2 and cancer: Breast cancers with HER2 positive expression had a slightly higher mPRα-HiEx rate compared to that in HER2 negative cancers (54.05% vs. 38.24%, P=0.12, Table 2); in addition, the HER2 positive cancers were also associated with a significant elevated level of mPRα expression, as compared to that in HER2 negative cancers (1.34±0.10 vs. 1.13±0.07, P=0.07).